Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06210594 · ClinicalTrials.gov registry record · Phase 4
Staph Intervention for Effective Local Defense
A Phase 4 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT06210594: Completed Phase 4 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT06210594 is a Phase 4 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 78 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06210594, a Phase 4 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. Participants will be assigned to education and household supplies for prevention of SA with and without a biomedical intervention. Researchers will compare SA carriage in the two groups.
Primary Outcome
Compare SA carriage prevalence in the nose, throat, and skin (any site) between arms.
Interventions
- COMBINATION_PRODUCT Mupirocin + Nozin + chlorhexidine gluconate
- BEHAVIORAL Education + Household supplies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-11-14 |
| Phase | Phase 4 |
What the finished NCT06210594 record still lists
NCT06210594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Mupirocin + Nozin + chlorhexidine gluconate is the first listed.
NCT06210594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06210594 about?
NCT06210594 is a clinical study titled "Staph Intervention for Effective Local Defense". Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. P...
What is the current status of trial NCT06210594?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2024-04-01. Estimated completion is 2025-11-14.
What interventions are being tested in trial NCT06210594?
The interventions under investigation include: Mupirocin + Nozin + chlorhexidine gluconate (COMBINATION_PRODUCT), Education + Household supplies (BEHAVIORAL).
Who is sponsoring clinical trial NCT06210594?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06210594's enrollment target sits among peer trials
78 982nd of 2000 higher than 1,012 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI